Introduction
Inflammation and hemostasis or thrombosis are integrated processes. [1] [2] [3] [4] Fibrin limits dissemination of microbes during implementation of the innate and adaptive immune response. 5, 6 Infection, inflammation and autoimmune disorders also increase the risk of thrombosis, [7] [8] [9] [10] [11] but the pathways that link these processes are incompletely understood.
Inflammation activates the contact pathway of coagulation by releasing bacterial and platelet polyphosphates, 12, 13 RNA, 14 DNA, 15 and sulfatides 16 when blood is exposed to microbial surfaces, 17 collagen, 18 and neutrophil extracellular traps 19 and on the surfaces of intravascular devices. 20 Mice lacking individual contact factors are less susceptible to developing thrombi in these settings. [21] [22] [23] Diverse approaches to impairing contact activation (eg, through the use of inhibitory antibodies to factor XIIa 24 and artificial antisense oligonucleotides to factor XI 25, 26 ) have provided thromboprophylaxis without increasing blood loss in some experimental and surgical 27 settings. These data suggest that novel approaches may be required to mitigate the risk of thrombosis induced by inflammatory pathways and exposed surfaces.
Neutrophils, a principal component of the innate immune system, contribute to the increased risk, severity, and adverse outcome of thrombosis, 28, 29 including stroke, [30] [31] [32] [33] by contributing to the rupture of atherosclerotic plaque (reviewed by Soehnlein 34 ), promoting platelet activation, 35 possible carriage of tissue factor, 36, 37 impairing the antithrombotic function of the endothelium, 36, [38] [39] [40] and impeding the response to fibrinolytics, 41 among other processes. A dose-dependent relationship between activated neutrophils, circulating nucleosomes, and development of deep vein thrombosis has been noted. stroke, and cardiovascular mortality. [45] [46] [47] a-Defs bind to endothelium and vascular smooth muscle cells, 48, 49 deposit in atherosclerotic human coronary and carotid arteries, 48, 50 promote platelet activation, 51, 52 inhibit tissue-type plasminogen activator (tPA)-mediated fibrinolysis in vitro, 53 impair lipoprotein metabolism, 54 and alter vascular reactivity, 55 but their involvement in thrombosis in vivo has not been established.
Investigation into the potential role of a-defs in vascular disorders such as thrombosis has been limited by the fact that unlike in humans, murine neutrophils lack these peptides. 56 , 57 Here, we investigated the role of a-defs both in fibrin formation and stability in vitro and in the pathogenesis of thrombosis in transgenic mice expressing a-Def-1, which comprises 70% of human neutrophil a-defs. The results show that a-defs released from human neutrophils upon activation of the contact pathway of coagulation accelerate clot formation and generate compact clots with enhanced resistance to fibrinolysis in vitro and induce heparin resistance and propagate thrombus formation in vivo. Inhibition of a-def synthesis or release causes phenotypic reversion and restores responsiveness to heparin.
Methods

Materials
Recombinant tPA and dabigatran were purchased from Boehringer Ingelheim (Ingelheim am Rhein, Germany); bovine serum albumin, Tris, kaolin, and prekallikrein were from Sigma (Saint Louis, MO); tissue factor was from Perrigo (Dublin, Ireland); thrombin was from Ilex (Petah Tekva, Israel), Omrix (Jerusalem, Israel), and Sigma; rivaroxaban was from Bayer (Whippany, NJ); aprotinin was from Kamada (Peit Kama, Israel); prekallekreindeficient plasma was from Technoclone (Vienna, Austria); and colchicine was from Rafa (Jerusalem, Israel). Active factors, XII, XI, and IX were from Kordia (Leiden, the Netherlands). Plasminogen was purified from human plasma using a tranexamic acid column from Omrix or American Diagnostica (Greenwich, CT).
Animal studies
All studies were conducted in accordance with the National Institutes of Health's Guide for the Care and Use of Laboratory Animals and approved by the institutional animal care and use committees of the Hebrew University, Jerusalem, Israel.
Measurements of the concentrations of a-defs in human plasmas and sera
The concentrations of a-defs in human and transgenic mouse plasmas and sera were measured by enzyme-linked immunosorbent assay (ELISA) as described previously. 54 See supplemental Methods (available on the Blood Web site) for experimental details.
a-Def-1 sources and radiolabeling
Two sources of a-Def-1 were employed. a-Def-1 was purchased from Peptide Institute (Osaka City, Japan). a-Def-1 was also kindly provided by Dr. Wuyan Lu (University of Maryland School of Medicine). a-Def-1 was radiolabeled with 125 I as reported previously. 48 See supplemental Methods for experimental details.
Binding of 125 I-a-def to fibrin(ogen)
Binding of a-Def-1 to fibrinogen and fibrin was measured as described previously. 48 See supplemental Methods for experimental details.
Dynamic clot turbidity
Clotting of purified fibrinogen was initiated by adding thrombin and CaCl 2 in the presence or absence of a-Def-1. Fibrin formation was evaluated by monitoring the change in optical density (turbidity) at absorbance at 405 nm (A 405 ). See supplemental Methods for experimental details.
Rate of fibrinolysis
Fibrin clots were formed as described above, but the A 405 was monitored for up to 4.5 hours. Plasminogen was added to the fibrinogen before addition of thrombin and either tPA or urokinase-type plasminogen activator (uPA) in the presence or absence of a-Def-1. Because the turbidities were far higher in the presence of a-Def-1, data were normalized based on maximal turbidity. See supplemental Methods for experimental details.
Isolation of neutrophils
Neutrophils were isolated 58, 59 and kept on ice until use. 60 See supplemental Methods for experimental details.
Immunofluorescent staining and confocal microscopy of fibrin clots
Hydrated fibrin clots formed in the presence or absence of a-Def-1 as described above were stained with an Alexa Fluor 568-conjugated anti-human fibrin mouse monoclonal antibody. Z-stacked images of immunolabeled fibrin networks were taken using a Zeiss LSM 710 laser scanning confocal microscope. Three-dimensional (3D) reconstruction, and maximal projection is shown. See supplemental Methods for experimental details.
Scanning electron microscopy
Fibrin clots formed in the absence or presence of a-Def-1 were washed, fixed, dehydrated, and sputter coated with goldpalladium as described previously. 61 Triplicate samples were examined using an FEI Quanta FEG250 scanning electron microscope (FEI, Hillsboro, OR). See supplemental Methods for experimental details.
Venous thrombosis in Def 11 mice
To study venous thrombosis, partial inferior vena cava (IVC) occlusion was performed 62 using a model that combines external compression with a reduction in blood flow. In some experiments, the effect of IV heparin on clot formation was determined. See supplemental Methods for experimental details.
Effect of neutrophil depletion, inhibition and bone marrow transplantation (BMT) on venous thrombosis in Def 11 mice
Partial IVC occlusion was performed as described previously. 62 In some experiments, mice were depleted of neutrophils 63 or were given colchicine in their drinking water to inhibit neutrophil degranulation 54 
Statistical analysis
Group comparisons was performed using the Student t test or 1-way analysis of variance with the Newman-Keuls post hoc test. 54, 64 Between-group comparisons were performed using the Mann-Whitney rank test and 2-way analysis of variance with the Newman-Keuls post hoc test. 64 Statistical significance was set at P , .05.
Results
Release of a-defs during blood coagulation in vitro
We first asked whether a-defs are released during clotting of whole blood in vitro. The concentrations of a-defs was over an order of magnitude higher in sera than in plasma of healthy volunteers (584 6 85 nM vs 18 6 3 nM, respectively; n 5 10, P , .001) ( Figure 1A ), indicating that a-defs are released during blood coagulation in vitro.
Release of a-defs is mediated by plasma kallikrein through activation of the contact factor pathway Plasma kallikrein stimulates release of neutrophil elastase from azurophilic granules, 65 where a-defs are stored. 66 Therefore, we asked whether the contact factors, including kallikrein, are also responsible for releasing a-defs from neutrophils. 67 Clotting of blood collected into a glass vacutainer was initiated in the absence of an anticoagulant to activate the contact pathway or by adding thrombin to bypass the contact pathway. Activating the contact pathway increased serum a-defs (530 6 62 nM), whereas thrombin did not (22 6 7 nM; Figure 1B) . Identical results were obtained using each of the 4 sources of thrombin. Clotting initiated by adding kaolin increased a-defs in sera to the same extent (891.5 6 162.3 nM). Release of a-defs by kaolin was inhibited by 400 KIU/mL aprotinin 68 and 50 mg/mL corn trypsin inhibitor (CTI), suggesting a role for factor XIIa (FXIIa) as well 69 ( Figure 1C) , and was proportional to the amount of kallikrein generated (supplemental Figure 1A-B) , consistent with activation of the contact factor pathway. On the other hand, clotting initiated by 5 pM tissue factor did not affect a-def release (19 6 13 nM) ( Figure 1C ; supplemental Figure 1B ). The thrombin inhibitor dabigatran and the FXa inhibitor rivaroxaban delayed clotting but did not inhibit release of a-defs by kaolin (data not shown). Coagulation initiated by tissue factor (0.2 nM) to back-activate the contact factor pathway and generate additional kallikrein caused a small added increase in a-def release that was susceptible to inhibition by CTI (supplemental Figure 1B) .
As an independent approach, neutrophils isolated from a healthy donor were added to autologous or prekallikrein-deficient plasma, and coagulation was initiated with kaolin. a-Defs were only released in the presence of endogenous or added prekallikrein (298 6 34 nM) ( Figure 1D ). a-Defs were also released from isolated human neutrophils incubated for 30 minutes at 37°C with purified FXIIa plus prekallikrein, which was inhibited by CTI and aprotinin, but release was not induced by prekallikrein alone or FXIIa, FXIa, FVIIa, and FXa alone in the presence or absence of prekallikrein ( Figure 1E ). Identical results were seen in whole blood (supplemental Figure 2 ). In contrast to the effect of zymogen-activated serum, kallikrein did not cause the release of myeloperoxidase in parallel with a-defs. 54 These data indicate that activation of the contact pathway initiates release of a-defs from neutrophils during clot formation.
Incorporation of a-defs into fibrin clots
We next asked whether a-defs released during clot formation are incorporated into the fibrin network. As a first approach, 125 I-a-Def-1 (7.5 mM final concentration) was added to a solution of fibrinogen (3 mg/mL), and clotting was initiated by thrombin (0.033 U/mL). Clots were separated by centrifugation, and radioactivity in the clots and supernatants was measured. Approximately 90% of the radiolabeled a-Def-1 was associated with the clot ( Figure 1F ). We then measured the concentration of a-defs in clots formed in human blood activated by kaolin or thrombin and then released by adding tPA and plasminogen. The concentration of a-defs released from lysed blood clots formed by activating the contact pathway was 14.4 6 1.9 mM compared with 1.1 6 0.4 mM released from clots formed by adding thrombin (P , .05) ( Figure 1G ).
Effect of a-Def-1 on clot formation in vitro
We next asked whether a-defs modulate fibrin formation, structure, and susceptibility to lysis. a-Def-1 increased the rate of fibrin polymerization assessed by dynamic clot turbidity and altered fibrin structure assessed by increased maximal clot turbidity in a dose-dependent manner (Figure 2A-B) . a-Def-1 also shortened the lag time to clot formation in a dose-dependent manner (7.0 6 0.2, 1.5 6 0.2, 3.1 6 0.2, and ,2.5 minutes in the presence of 0, 1, 2.5, and 5.0 mM a-Def-1, respectively). The same effect was observed when supernatants from isolated neutrophils activated by 100 ng/mL phorbol 12-myristate 13-acetate or FXIIa plus prekallikrein were added instead of purified a-Def-1 (supplemental Figure 3A -B). Release of a-defs by neutrophils was not induced by FXIIa alone, when cells were stimulated in the presence of CTI or aprotinin (supplemental Figure 3A-B) , or by the presence of 3 mg/mL fibrinogen (data not shown).
We next asked whether a-defs enhance clot formation by stimulating thrombin activity or whether the effects of a-defs are mediated through binding to fibrin(ogen). a-Def-1 (2 mM) did not stimulate the amidolytic activity of thrombin but rather exerted a slight inhibition at higher concentrations (10 mM) ( Figure 2C ). Little 125 I-a-Def-1 bound directly to fibrinogen as assessed by gel filtration, whereas 92.3% of the radioactivity was found in the eluted fractions that contained soluble fibrin ( Figure 2D ). Together, these data suggest that a-defs accelerate fibrin formation primarily by interacting with intermediate fibrin oligomers.
Effect of a-Def-1 on clot structure in vitro
We then studied the effect of a-defs on the final structure of the fibrin network using confocal microscopy. In the presence of 5 mM a-Def-1, fibrin formed spatially nonhomogenous networks in which areas of dense and highly branched fibers were interspersed with large pores ( Figure 3A ). Scanning electron microscopy revealed that a-Def-1 caused bundling, entanglement, and partial conglutination of fibrin fibers resulting in the formation Blood collected from healthy volunteers in citrate to prepare plasma was allowed to sit at room temperature for 1 hour to prepare serum. Blood was centrifuged at 1500g for 10 minutes, and the concentration of a-defs 1-3 in the plasma and serum was measured by ELISA. 54 The results shown are the mean 6 SD from 10 human healthy volunteers (*P 
Effect of a-Def-1 on fibrinolysis in vitro
Based on these changes in fibrin structure, we assessed the impact of a-defs on tPA-induced lysis of fibrin made from purified fibrinogen in the presence of plasminogen. The time to attain 50% lysis of the fibrin clots was prolonged in the presence of increasing concentrations of a-Def-1 ( Figure 4A-B) .
Notably, lysis was incomplete, with large pieces of fibrin remaining even after a 3-hour exposure to tPA. The amount of residual lysis-resistant fibrin was roughly proportional to the concentration of a-Def-1 ( Figure 4C ). The same inhibitory effect on fibrinolysis was obtained by adding supernatants from purified neutrophils activated with phorbol 12-myristate 13-acetate or FXIIa plus prekallikrein, but not by using FXIIa or prekallikrein alone, and the effect was prevented by CTI (supplemental Figure 4A) . Fibrinolysis mediated by tPA, but (D) Binding of a-defs to fibrinogen and fibrin. 125 I-a-Def-1 (5 mg/mL; 28 mM), twice the concentration found in fibrin clots ( Figure 1G ), was incubated with fibrinogen (100 mg/mL) (:) or soluble fibrin 87 (100 mg/mL) (4) in 200 mL PBS or PBS alone (s) for 60 minutes at 24°C. The mixture was loaded onto a Sephacryl S-100 gel filtration column, and radioactivity and optical density (OD) at 280 nm in each 0.5-mL fraction eluted from the column were measured. One experiment representative of 3 in shown. For personal use only. on January 31, 2019. by guest www.bloodjournal.org From not uPA, is inhibited when a-defs were added to preformed clots. 59 In contrast, uPA-mediated lysis was blocked when a-def was added during clot formation together with plasminogen and uPA (supplemental Figure 4B) . These results support the conclusion that a-defs bind to nascent fibrin (Figure 1F 
a-Def release and effect on fibrin formation and lysis ex vivo
The addition of kaolin to blood from transgenic mice (Def 11 ) that expresses human a-Def-1 in their neutrophils 56 increased the plasma concentration of a-defs from 15 6 3 nM to 94 6 7 nM, which was prevented by CTI and aprotinin (supplemental Figure 1) . Over 90% of the a-defs released were incorporated into fibrin during clot formation (supplemental Figure 5 ), as seen with human blood ( Figure 1G ). Blood from Def 11 mice clotted more rapidly, and the clots took longer to lyse (as assessed by thromboelastography) than did clots formed using blood from WT mice that do not express a-defs ( Figure 5A ) (R value in WT and Def 11 mice, 7.4 6 0.7 and 4.6 6 0.6 min, respectively; n 5 13 per group; P , .05). Rapid clotting in Def 11 mice was preceded by an increase in a-defs in the media detected 3 minutes after the addition of kaolin (data not shown).
Prothrombotic effects of a-defs in vivo
We then compared outcomes in the IVC stasis model of thrombosis in Def 11 and WT mice. Plasma levels of a-Def-1 rose from 17 6 1 nM to 66 6 5 nM after IVC occlusion in Def 11 mice (n 5 23; P , .05), and the clot content of a-defs was 1.44 6 0.16 mM, which is comparable to the incorporation of a-defs in vitro (supplemental Figure 5) . Every Def 11 mouse developed IVC thrombi compared with 44% of WT mice (n 5 13, P , .05). Clots formed in Def 11 mice were overtly larger than those formed in WT mice based on their appearance in situ ( Figure 5C ) and visual inspection postextraction ( Figure 5D-E) . IVC thrombi formed in Def 11 mice weighed on average ;10-fold more than clots formed in WT mice ( Figure 5D -E) (29.3 6 3.5 vs 3.5 6 0.6 mg; P , .001) and contained more neutrophils (591 6 93 vs 86 6 24 cells per field, P , .05) ( Figure 5D ), consistent with findings by others that a-defs promote neutrophil migration. 70 Scanning electron microscopy of the fibrin meshwork of thrombi extracted from Def 11 mice showed more fibrin on the clot
10 000x Figure 3 . Effects of a-Def-1 on fibrin structure. (A) Representative 3D confocal microscopy images of fibrin clots formed from fibrinogen in the absence (left) or presence (right) of 5 mM a-Def-1. Fibrin was visualized using Alexa Fluor 647-labeled fibrinogen. (B) Representative scanning electron micrographs of fibrin clots formed in the absence (left) or presence (right) of 5 mM a-Def-1 at original magnification 32000 and 310 000. Three individual clots were studied at each experimental condition. Scale bars represent 30 mm (top) and 5 mm (bottom).
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blood® 31 JANUARY 2019 | VOLUME 133, NUMBER 5 Figure 5F , a, red arrows) than was seen in thrombi removed from WT mice ( Figure 5F, b) , and they contained a higher proportion of tightly packed compressed polyhedral red blood cells (polyhedrocytes) within their interiors ( Figure 5F , c, blue arrows), a morphologic signature of platelet-driven clot contraction, 61 compared with thrombi from WT mice ( Figure 5F, d) .
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Phenotypic conversion by preventing a-Def-1 release
We previously reported that addition of colchicine to the drinking water of Def 11 mice prevented neutrophil degranulation, lowered the plasma level of a-Def-1, and prevented their pathological effect on lipoprotein metabolism. 54 Therefore, we next compared thrombus development in Def 11 mice given colchicine or saline in their drinking water for 2 weeks prior to inducing IVC stenosis. Pretreatment with colchicine decreased levels a-Def-1 in the circulation of Def 11 mice ( Figure 6A) concomitant with a decrease in the size of clots that developed in the IVC ( Figure 6B) , with no comparable effect on clot size in WT mice (supplemental Figure 6A-B) . The fibrin network on the surface of the thrombi extracted from Def 11 mice given colchicine was less dense ( Figure 6C, c) , and there were fewer tightly packed polyhedrocytes within the clot interior, as viewed by scanning electron microscopy ( Figure 6C, d) , than in thrombi from untreated animals ( Figure 6C, a and b, respectively) . Depletion of neutrophils in Def 11 mice diminished clot size to that seen in WT mice without affecting clot size in WT mice (supplemental Figure 6A-B) . Clot size was also decreased in Def 11 mice given CTI prior to stenosis (supplemental Figures 7 and 8) .
We also previously reported that transplanting bone marrow from WT mice into Def 11 mice prevented formation of a-Def-1/ low-density lipoprotein complexes and the development of early atherogenic changes in aortic roots in animals on a normal chow For personal use only. on January 31, 2019. by guest www.bloodjournal.org From diet, whereas the converse was true when WT mice were transplanted with bone marrow from Def 11 mice. 54 Therefore, we used crosstransplantation as an independent method to assess the effect of a-Def-1 on IVC thrombosis. Plasma levels of a-Def-1 in WT mice transplanted with Def 11 marrow reached levels seen in Def 11 mice by week 4 posttransplant (15.8 6 2.0 nM in transplanted mice vs 16.7 6 1.3 nM in Def 11 mice).
Conversely, a-Def-1 became undetectable in the plasma of Def 11 mice transplanted with WT BM by this time ( Figure 6A ). Concomitant with the rise in plasma a-Def-1, WT mice transplanted with Def 11 BM developed clots similar in size to those seen in Def 11 mice ( Figure 6B ), whereas IVC thrombi in Def 11 mice transplanted with WT bone marrow were similar to those seen in WT mice ( Figure 6B ). 
Resistance to heparin
Addition of a-defs to blood activated by kaolin attenuated the prolongation in clot time (R value) caused by heparin as measured by thromboelastography ( Figure 5A ). Therefore, we next asked whether endogenous release of a-Def-1 impaired the antithrombotic effectiveness of heparin in vivo. An IV bolus of saline or increasing doses of heparin or colchicine (or both) were given 1 hour after the onset of IVC stenosis and every 12 hours thereafter, and clot size was measured at 72 hours. Def 11 mice required ;20-fold more heparin than WT mice (200 U/kg vs 10 mg/kg, P , .05) to prevent clot formation ( Figure 7A ). Figure 7D ). When Def 11 mice were given a subtherapeutic dose of colchicine (0.1 mg/kg) combined with an "ineffective" dose of heparin (10 U/kg), thrombus size was reduced on average by 60% (P , .05) ( Figure 7E ) without an increase in tail bleeding ( Figure 7E ). For personal use only. on January 31, 2019. by guest www.bloodjournal.org From
Discussion
Inflammation and thrombosis are closely linked processes. Fibrin contributes to the innate immune response by impeding tissue invasion by microbial pathogens, 71, 72 providing a provisional matrix to direct initially neutrophils and later macrophages to their targets, and stimulating cytokine release from leukocytes, 73 among other impacts on the host response. 74 The multiplicity of processes associated with "inflammatory thrombosis" includes pathways that are not directly responsive to antithrombotic management directed at the extrinsic pathway and generation of thrombin. 2 Rapid recruitment of neutrophils to sites of thrombosis as the result of ischemic injury contributes to impaired responsiveness to fibrinolytic . WT mice (red) and Def 11 mice (blue) were given heparin alone. WT mice (purple) and Def 11 mice (green) were given heparin and colchicine. Clots were extracted and weighed 72 hours after stenosis (*, #, &, P , .05). (B) IVC stenosis was induced as in panel A. One hour later, mice were given IV saline (n 5 9), colchicine (0-0.5 mg/kg) (n 5 17), a fixed dose of heparin (10 U/kg) (n 5 14), or heparin 1 colchicine (n 5 14). WT mice (red) and Def 11 mice (blue) were given colchicine alone. WT mice (purple) and Def 11 mice (green) were given heparin and colchicine. Clots were extracted and weighed 72 hours after stenosis (*, #, P , .05). (C-D) Effect of colchicine on bleeding. (C) Mice were treated as in panel A. Tail-bleeding times were measured at 72 hours after receiving the indicated doses of heparin, colchicine, or both. WT mice (red) and Def 11 mice (blue) were given heparin alone. WT mice (purple) and Def 11 mice (green) were given heparin and colchicine. (D) The hemoglobin concentration in blood extravasated during the initial 30 minutes after transection. WT mice (red) and Def 11 mice (blue) were given heparin alone. WT mice (purple) and Def 11 mice (green) were given heparin and colchicine (*, #, P , .05). (E) Clot weight (red) and tail-bleeding times (blue) were measured 72 hours after IVC stenosis, followed 1 hour later by IV administration of colchicine (0.1 mg/kg) (n 5 14), heparin (10 U/kg) (n 5 14), or both (n 5 11), as described in panel A. The mean 6 SD are shown (*, #, P , .05).
490
blood® 31 JANUARY 2019 | VOLUME 133, NUMBER 5
ABU-FANNE et al
For personal use only. on January 31, 2019. by guest www.bloodjournal.org From therapy and reperfusion injury. 75 However, the mechanisms by which neutrophils enhance clot formation and impair clot resolution are incompletely defined.
The results of this study show that neutrophil-derived a-defs promote clot formation. a-Defs, at concentrations that develop under pathological conditions bind directly to nascent fibrin. Binding of a-defs accelerates fibrin polymerization, increases fibrin mass, and impairs fibrinolysis. These effects of a-defs may contribute to their antimicrobial function by accelerating the formation and enhancing the stability of the fibrin shield that acts as an early barrier against microbial infiltration.
76 Moreover, the high local concentration of a-defs released rapidly following coagulation may generate high local concentrations of antimicrobial activity that precede neutrophil migration and egress into inflamed tissue.
However, a-defs incorporated into fibrin during clotting also altered clot architecture, forming a nonhomogeneous network showing areas of densification interspersed with large pores. Bundling and entanglement of fibers lead to formation of abnormal fibrin networks that have been associated previously with a prothrombotic phenotype in a number of pathological conditions, including those with a strong inflammatory component and recruitment of neutrophils. [77] [78] [79] [80] Such changes in fibrin structure influence its susceptibility to lysis and mechanical properties. [81] [82] [83] Thus, the profound effect of a-defs on clot formation in vitro and in vivo can be attributed to alterations of fibrin structure described here, as well as to the previously described inhibitory effects on tPA-mediated fibrinolysis. 53, 59 These data help to explain how incorporation of a-defs into clots may contribute to an increased tendency for thrombus formation and incomplete fibrinolysis that might lead to incomplete vascular recanalization. 84 The effects of a-defs on clot formation were also seen in vivo. a-Def-1, the most prevalent a-def in human neutrophils, is released when clotting is initiated in a transgenic mouse. a-Def-1 transgenic mice formed dramatically larger venous thrombi than WT mice. Thrombi formed in a-Def-1-expressing mice were also more resistant to dissolution by tPA. Indeed, thrombi extracted from Def 11 mice contained a high proportion of tightly packed polyhedral red blood cells (polyhedrocytes), 61 as revealed by scanning electron microscopy, a morphologic signature of intense clot contraction ( Figure 6 ). The more extensive clot contraction seen in Def 11 mice might retard the diffusion of lytic enzymes and thereby increase resistance to fibrinolysis.
These observations provide a newly described link between activation of the contact factor pathway during inflammation and thrombosis, and they suggest that pharmacological inhibition of thrombin (eg, by heparin) might not suffice to prevent release of a-defs and the resultant enhancement of clot stability. In our studies, clot formation was induced in the IVC in the absence of an apparent direct activation of neutrophils. Thrombus formation itself, whether through back activation of the contact factor pathway as shown here, local hypoxia, an effect of fibrin on the prothrombotic properties of the vessel wall, or vascular release of cytokines may cause sufficient release of a-defs from neutrophils to dramatically enlarge clot mass and stability. This outcome may help to explain the incomplete response to anticoagulant and fibrinolytic agents in clots invested with neutrophils 1 and suggests that inhibitors of the contact factor pathway might attenuate clot formation and hasten resolution even in the absence of overt inflammation. These results also suggest that addition of drugs that inhibit the contact factor pathway or inhibit neutrophil degranulation may enhance the efficacy of inhibitors of thrombin or FXa without significantly increasing the risk of bleeding. 85 Phenotypic reversion of a-def levels in plasma and thrombus formation were induced in a-Def-1 mice by BMT from WT mice and provision of colchicine in the drinking water. Colchicine has been used safely for decades to reduce neutrophil activation in patients with familial Mediterranean fever and more recently in patients with gout, osteoarthritis, or pericarditis, and a protective effect has been seen against myocardial infarction and possibly stroke. 86 Def 11 mice required 20-fold more heparin to prevent IVC thrombosis than WT mice. Intravenous colchicine lowered the effective anticoagulant dose of heparin to that which was effective in WT mice, with no discernable impact on hemostasis, as assessed by tail vein bleeding time or blood loss following tail transection. Additional studies will be needed to more fully understand the effect of a-defs on clot formation and structure and determine whether colchicine or other agents that prevent neutrophil degranulation provide a useful adjunctive approach to treat or prevent thrombosis that develops in the context of neutrophil activation and systemic inflammation.
